One of the biggest health challenges affecting the modern world is depression and substance addiction. The treatments for these conditions vary, but almost always end up in prescription pills. The U.S. military seems determined to change this, according to reports reaching media houses.
Over the years, people have visited therapists and psychiatrists seeking help due to depression, anxiety, stress, and PTSD (post-traumatic stress disorder), and doctors prescribe drugs to help them with these situations. Of recent, governmental departments, one being DARPA (Defense Advanced Research Projects Agency), have started investing in researching for a new class of drugs that will enhance the success rates of the treatments of these conditions. But as we have witnessed in the past, most drugs have their pros and cons. This new class of drugs offers treatment with psychedelics. But the question raised is, “Does treatment with psychedelics necessarily require a psychedelic experience?”
Most therapeutic drugs for mental conditions are antidepressants. Some have significant side effects like nausea, fatigue, insomnia, and maybe some constipation. The agencies tasked with creating these new drugs are trying to minimize such side effects while creating a rapid treatment option for the patients involved. DARPA, while trying to enclose their research, didn’t mention specifics, but they stated that the drugs being produced interacted with serotonin receptors and have significant side effects like hallucinations. They added that the desired drugs would be non-addictive in nature. This would address a global challenge of non-addictive antidepressants, noting that most of the drugs that have been used in the past as antidepressants have later led to addiction.
The U.S. Department of Defense, through DARPA; is involving a large amount of money (reportedly over $27 million) in this research. They are trying to help veterans who are facing mental health conditions, and most of those veterans are dealing with PTSD and depression. Some are affected while they still serve the military. Things are expected to change after the finalization of an antidepressant drug with faster response rates. This research is aimed at benefiting not only the military, but any civilian battling depression or PTSD.
The involvement of the military, and the government at large, in the use of psychedelics to treat psychological disorders has been largely welcomed by activists. Psychedelic substances have been for ages restricted by the controlled substances act and the UN conventions, exceptions being made only for religious or research purposes.
This is not the first time psychedelics are being used as curative medicines. The use of psychedelics like mescaline containing cacti (Peruvian torch and Peyote) by Native Americans to treat alcoholism is a good example.
Industry experts say psychedelics companies like Psy Bio Therapeutics Inc. could be pleased that crucial federal government departments are taking the big step of exploring psychedelics as an alternative to existing mental health medications.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.